Alexander and Canavan Disease by SHALBAFAN, Bita
Iran J Child Neurol. 2014 Autumn Vol 8 No 4  Suppl. 1
Alexander and Canavan Disease
How to Cite This Article: Shalbafan B. Alexander and Canavan Disease. Iran J Child 
Neurol. Autumn 2014;8;4(Suppl.1):20-21.
Bita SHALBAFAN MD
Neurologist, Specialist on 
Neurometabolic Disorders, 




North Kargar Ave, Nosrat St, 




Alexander disease is a rare genetic disorder that predominantly affects infants and 
children and is associated with cerebral white matter disease.
Intracytoplasmicastrocytic inclusions known as Rosenthal fibers are the hallmark 
of Alexander disease.Sporadic mutations in the GFAP gene are the cause of most 
cases of Alexander disease.
Four subtypes of Alexander disease — neonatal, infantile, juvenile, and adult — are 
traditionally recognized but a revised classification of Alexander disease proposes 
two subtypes – types I and II – based upon statistical analyses:
type I is characterized by early onset, seizures, macrocephaly, motor delay, 
encephalopathy, sudden deterioration, and typical neuroimaging features
Type II onset may occur across the lifespan, and is characterized by autonomic 
dysfunction, eye movement abnormalities, bulbar symptoms, and atypical 
neuroimaging features
Typical MRI features of Alexander disease are:Extensive cerebral white matter 
changes with frontal predominance, Periventricular rim of high T1 signal and low 
T2 signal, Basal ganglia and thalamic abnormalities, Brainstem abnormalities, 
Contrast enhancement of selected gray and white matter structures
Less common MRI features of Alexander disease include: Multifocal brainstem 
lesions resembling multiple tumors, Medullary and cervical spinal cord signal 
abnormalities or atrophy and Ventricular garlands
The diagnosis of Alexander disease can be established based upon clinical and 
radiographic (MRI) features. The diagnosis is usually confirmed by demonstrating 
a GFAP gene mutation. Although genetic testing is not necessarily required for the 
diagnosis, genetic confirmation should always be attempted due to the heterogeneity 
of the disease and its presentation. 
The differential diagnosis of Alexander disease involves consideration of other 
disorders that present with macrocephaly and/or cerebral white matter changes.
Treatment of Alexander disease remains supportive.
Canavan disease or aspartoacylase deficiency is an autosomal recessive spongiform 
leukodystrophy that is prevalent in the Ashkenazi Jewish population. The disease 
typically begins in infancy and is marked by relentless progression.
Aspartoacylase deficiency is caused by mutations in the ASPA gene that encodes 
the enzyme aspartoacylase. The resulting deficiency of aspartoacylase leads to 
accumulation of N-acetylaspartic acid (NAA) in brain and to oligodendrocyte 
dysfunction, spongiform changes, and absence of myelin. However, the precise 
mechanisms causing to spongiform degeneration are uncertain.
Aspartoacylase deficiency typically presents at about age three months with 
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lethargy and listlessness, weak cry and suck, poor head 
control, and hypotonia with a paucity of extremity 
movement. Macrocephaly becomes prominent by 
three to six months. Thereafter hypotonia progresses to 
spasticity and tonic extensor spasms. By age six months, 
neurologic abnormalities are invariant. Little subsequent 
development is noted. Blindness from optic atrophy 
occurs between 6 and 18 months. Seizures are noted in 
about 50 percent of patients. Pseudobulbar signs and 
decerebrate posturing dominate the end stage.
The presence of variant forms of aspartoacylase 
deficiency is controversial.
Brain imaging by CT and MRI reveals diffuse and 
symmetrical white matter involvement.
The gross pathologic findings are dominated by spongy 
degeneration of deep cortex, subcortical white matter, 
and cerebellum. The spongiform changes reflect 
vacuolated astrocytes in deeper cortical layers and in 
adjacent subcortical white matter. 
In symptomatic infants with compatible clinical features 
(eg, hypotonia, poor head control, macrocephaly) and 
neuroimaging findings, the diagnosis of aspartoacylase 
deficiency is supported by elevated levels of urine 
N-acetylaspartic acid (NAA) and deficient aspartoacylase 
activity in cultured skin fibroblasts. Genetic testing may 
be obtained for purposes of genetic counseling. 
The differential diagnosis of aspartoacylase deficiency 
includes other progressive white matter diseases of 
infancy, particularly Krabbe disease, metachromatic 
leukodystrophy, early-onset adrenoleukodystrophy, 
Alexander disease, and demyelinating disorders.
No effective treatment is available for aspartoacylase 
deficiency. Management is supportive and aimed at 
maintaining nutrition and hydration, protecting the 
airway, preventing seizures, minimizing contractures, 
and treating infections.
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